Aβ-binding alcohol dehydrogenase (ABAD)

The interaction of amyloid-beta with ABAD represents a pathogenic mechanism in Alzheimer's disease. ABAD is a mitochondrial enzyme, part of the short-chain dehydrogenase/reductase family, with key roles in energy metabolism and RNA processing. Binding of Aβ to ABAD "distorts the enzyme's active site, impairs its metabolic functions, and promotes mitochondrial generation of reactive oxygen species (ROS)[1][2][6]." This interaction is believed to contribute to mitochondrial dysfunction, neuronal toxicity, and disease progression. Targeting Aβ-ABAD binding (for example, with small molecule inhibitors such as AG18051) has shown promise in preclinical models for mitigating Aβ-induced mitochondrial damage, although the precise mechanisms and safety remain under investigation[2][6]. This target is particularly relevant in the context of Alzheimer's disease drug development and research on mitochondria-mediated neurodegeneration.

Other names

ABADSDR5C1HSD17B10Amyloid-beta-binding alcohol dehydrogenase

Competitive inhibition of Aβ–ABAD binding